Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.
Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
